Prof Arun Azad
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
522 Scholarly works
10 Projects
HIGHLIGHTS
2026
Journal article
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
DOI: 10.1007/s10928-026-10038-72026
Journal article
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
DOI: 10.1038/s41467-026-74255-x2026
Journal article
Germline CDK12 variants in aggressive prostate cancer.
DOI: 10.1158/2159-8290.CD-26-00842026
Journal article
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
DOI: 10.1016/j.eururo.2026.03.0242023
Research grants (ARC, NHMRC, MRFF)
Optimising Radiopharmaceutical Therapy to Improve Clinical Outcomes in Advanced Prostate Cancer
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Research Grant
Vca Clinical Research Fellowship
RECENT SCHOLARLY WORKS
2026
Journal article
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
DOI: 10.1158/1078-0432.CCR-25-40012026
Journal article
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
DOI: 10.1016/j.eururo.2025.08.0152026
Journal article
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.
DOI: 10.1158/1078-0432.CCR-26-08712026
Journal article
Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.
DOI: 10.2967/jnumed.126.2725312026
Journal article
TALAPRO-3: Talazoparib (TALA) enzalutamide (ENZA) compared with placebo (PBO) ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.
DOI: 10.1200/jco.2026.44.17_suppl.lba50072026
Journal article
Germline genetic correlates in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus non-steroidal anti-androgen (NSAA) or enzalutamide (ENZA): Correlative study of ENZAMET (ANZUP 1304).
DOI: 10.1200/jco.2026.44.16_suppl.5099
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Understanding Biomarkers of Response and Resistance to 177-Lutetium-Psma (LuPSMA) in Metastatic Castrate-Resistant Prostate Cancer
2023
Research grants (other domestic)
Using Liquid Biopsies to Optimise Prostate Cancer Radionuclide Therapy